論文・著書
～2021年
Therapeutic efficacy of lenvatinib for hepatocellular carcinoma with iso-high intensity in the hepatobiliary phase of Gd-EOB-DTPA-MRI
Kuwano A, Tanaka K, Yada M, Nagasawa S, Morita Y, Masumoto A, Motomura K
Molecular and Clinical Oncology 16(2) : 53 2021-12
ペムブロリズマブによる硬化性胆管炎に対しステロイドパルス療法が著効した1例
長澤滋裕 、宮﨑将之 、森田祐輔 、田中紘介 、矢田雅佳 、増本陽秀 、本村健太
日本消化器病学会雑誌 118(10): 981-990, 2021-10
Upregulated expression of hypoxia reactive genes in peripheral blood mononuclear cells from chronic liver disease patients
Kuwano A, Tanaka M, Suzuki H, Kurokawa M, Imoto K, Tashiro S, Goya T, Kohjima M,
Kato M, Ogawa Y
Biochem Biophys Rep 27 : 101068 2021-07
Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial.
Kudo M, Motomura K, Wada Y, Inaba Y, Sakamoto Y, Kurosaki M, Umeyama Y, Kamei Y,
Yoshimitsu J, Fujii Y, Aizawa M, Robbins PB, Furuse J
Liver Cancer 10(3) : 249-259, 2021-06
Hypoxic hepatitis with marked elevation of serum ferritin probably due to activation of intrahepatic macrophages: another form of hypoxic hepatitis hitherto not reported?
Tanaka M, Goya T, Suzuki H, Takahashi M, Imoto K, Kurokawa M, Tashiro S, Kuwano A,
Okada S, Kato M, Kohjima M, Kotoh K, Ogawa Y
Acta Gastroenterol Belg 84(2) : 317-320, 2021-06
A case of granulocyte colony-stimulating factor-producing intrahepatic sarcomatoid cholangiocarcinoma.
Kuwano A, Narutomi F, Nagasawa S, Tanaka K, Morita Y, Yada M, Ohishi Y, Masumoto A,
Motomura K
Clin J Gastroenterol 14(3) : 881-887, 2021-06
Microcirculatory disturbance in acute liver injury.
Kuwano A, Kurokawa M, Kohjima M, Imoto K, Tashiro S, Suzuki H, Tanaka M, Okada S,
Kato M, Ogawa Y
Exp Ther Med 21(6) : 596, 2021-06
Metabolic Alteration in Hepatocellular Carcinoma: Mechanism of Lipid Accumulation in Well-Differentiated Hepatocellular Carcinoma.
Suzuki H, Kohjima M, Tanaka M, Goya T, Itoh S, Yoshizumi T, Mori M, Tsuda M, Takahashi M,
Kurokawa M, Imoto K, Tashiro S, Kuwano A, Kato M, Okada S, Nakamuta M, Ogawa Y
Can J Gastroenterol Hepatol 10 : 1155, 2021-02
Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab.
Zhu AX, Finn RS, Kang YK, Yen CJ, Galle PR, Llovet JM, Assenat E, Brandi G, Motomura K,
Ohno I, Daniele B, Vogel A, Yamashita T, Hsu CH, Gerken G, Bilbruck J, Hsu Y, Liang K, Widau RC, Wang C, Abada P, Kudo M
Br J Cancer 124(8) : 1388-1397, 2021-02
Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study.
Kudo M, Tsuchiya K, Kato N, Hagihara A, Numata K, Aikata H, Inaba Y, Kondo S,
Motomura K, Furuse J, Ikeda M, Morimoto M, Achira M, Kuroda S, Kimura A
J Gastroenterol 56(2) : 181-190, 2021-01
A randomized, double-blind, placebo-controlled, phase 3 study of tivantinib in Japanese patients with MET-high hepatocellular carcinoma.
Kudo M, Morimoto M, Moriguchi M, Izumi N, Takayama T, Yoshiji H, Hino K, Oikawa T,
Chiba T, Motomura K, Kato J, Yasuchika K, Ido A, Sato T, Nakashima D, Ueshima K,
Ikeda M, Okusaka T, Tamura K, Furuse J
Cancer Science 111(10) : 3759-3769, 2020
Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2.
Kudo M, Galle PR, Llovet JM, Finn RS, Vogel A, Motomura K, Assenat E, Merle P, Brandi G,
Daniele B, Okusaka T, Tomasek J, Borg C, Dadduzio V, Morimoto M, Pracht M, Jen MH,
Drove Ubreva N, Widau RC, Shinozaki K, Yoshikawa R
Liver International 40(8) : 2008-2020, 2020
B型慢性肝炎患者に出現した肝トキソカラ症の1例
福谷洋樹 、宮崎将之 、森田祐輔 、田中紘介 、矢田雅佳 、増本陽秀 、本村健太
日本消化器病学会雑誌 117（3） : 270-276, 2020
Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein:Japanese subgroup analysis of the REACH-2 trial
Kudo M, Okusaka T, Motomura K, Ohno I, Morimoto M, Seo S, Wada Y, Sato S, Yamashita T,
Furukawa M, Aramaki T, Nadano S, Ohkawa K, Fujii H, Kudo T, Furuse J, Takai H, Homma G,
Yoshikawa R, Andrew X
J Gastroenterol 55 : 627-639, 2020
Hepatocellular carcinoma recurrence in HCV patients treated with direct-acting antivirals after curative treatment
Shinichiro Nakamura, Kazuhiro Nouso, Hiroyuki Okada, Hideki Onishi, Shin-ichi Fujioka,
Yasuyuki Araki, Shouta Iwadou, Takashi Kumada, Hidenori Toyoda, Kenta Motomura,
Kazuya Kariyama, Haruhiko Kobashi, Toshihiko Kaneyoshi, Masaharu Ando, Akio Moriya,
Hideaki Taniguchi, Youichi Morimoto, Hiroaki Hagihara, Masatoshi Tanaka
Hepatoma Research 5(16) : 1-11, 2019
当院のレンバチニブによる肝細胞癌治療の実際
本村健太 、矢田雅佳 、宮﨑将之 、田中紘介 、増本陽秀
レンバチニブによる肝細胞癌治療 : 工藤正俊 : 株式会社アークメディア:pp257-265, 2019
Ramucirumab after sorafenib in patients with advancedhepatocellular carcinoma and increased α-fetoproteinconcentrations (REACH-2): a randomised, double-blind,placebo-controlled, phase 3 trial
Andrew X Zhu, Yoon-Koo Kang, Chia-Jui Yen, Richard S Finn, Peter R Galle, Josep M Llovet,
Eric Assenat, Giovanni Brandi, Marc Pracht, Ho Yeong Lim, Kenta Motomura, Izumi Ohno,
Philippe Merle, Bruno Daniele, Dong Bok Shin, Guido Gerkin, Christophe Borg,
Jean-Baptiste Hiriart, Takuji Okusaka, Manabu Morimoto, Yanzhi Hsu, Paolo B Abada,
Masatoshi Kudo
Lancet Oncology 20 (2) : 282-296, 2019
Hepatocellular carcinoma or interferon-based therapy history attenuates sofosbuvir/ribavirin for Japanese genotype 2 hepatitis C virus
Yada M, Miyazaki M, Tanaka K, Masumoto A, Motomura K
World Journal of Gastroenterology 24(13) : 1478-1485, 2018
Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma
Miyazaki M, Yada M, Tanaka K, Senju T, Goya T, Motomura K, Kohjima M, Kato M,
Masumoto A, Kotoh K
World Journal of Gastroenterology 23(29) : 5379-5385, 2017
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial
Kudo M, Hatano E, Ohkawa S, Fujii H, Masumoto A, Furuse J, Wada Y, Ishii H, Obi S,
Kaneko S, Kawagoe S
Journal of Gastroenterology 52(4) : 495-503, 2017
B型肝炎に対するアデホビル長期投与による腎機能障害と低P血症の検討
宮﨑将之 、本村健太 、正月泰士 、千住猛士 、矢田雅佳 、増本陽秀
肝臓 57(9) : 468-474, 2016
The prognostic role of lactate dehydrogenase serum levels in patients with hepatocellular carcinoma who are treated with sorafenib: the influence of liver fibrosis
Yada M, Miyazaki M, Motomura K, Masumoto A, Nakamuta M, Kohjima M, Sugimoto R,
Aratake Y, Higashi N, Morizono S, Takao S, Yamashita N, Satoh T, Yamashita S,
Kuniyoshi M, Kotoh K
Journal of Gastrointestinal Oncology 7(4) : 615-623, 2016
Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.
Yada M, Masumoto A, Motomura K, Tajiri H, Morita Y, Suzuki H, Senju T, Koyanagi T
World Journal of Gastoroenterology 20(35) : 12581-12587, 2014
口腔内感染に起因すると考えられたFusobacterium肝膿瘍の2例
千住猛士 、増本陽秀 、森田祐輔 、矢田雅佳 、小柳年正 、本村健太
肝臓 54（5） : 347-353, 2013
Stage IV進行肝細胞癌治療の標準化
矢田雅佳 、増本陽秀
消化器内科55(5) : pp662-668, 2012
多発肺転移巣が自然退縮した肝細胞癌の2例
千住猛士 、増本陽秀 、小柳年正 、田尻博敬 、矢田雅佳 、本村健太
肝臓 53(7) : 417-424, 2012
神経線維腫症1型（von Recklinghausen 病）に合併した肝内胆管癌の1剖検例
小柳年正 、増本陽秀 、田尻博敬 、矢田雅佳 、千住猛士 、本村健太 、大屋正文
肝臓 53(4) : 231-236, 2012
ライム病による急性肝炎の1例
田尻博敬 、増本陽秀 、矢田雅佳 、千住猛士 、本村健太 、小柳年正
肝臓 51(8) : 425-430, 2010
Immediate virological response predicts the success of short-term peg-interferon monotherapy for chronic hepatitis C
Yada M, Masumoto A, Yamashita N, Motomura K, Koyanagi T, Sakamoto S
World Journal of Gastoroenterology 16(12) : 1506-1511, 2010
Pravastatinによる薬剤起因性自己免疫性肝炎が潜在性に進行し肝硬変に至ったと考えられる1例
田尻博敬 、増本陽秀 、矢田雅佳 、千住猛士 、本村健太 、小柳年正 、大屋正文
肝臓 51(2) : 71-77, 2010
